The coronavirus disease 2019 (COVID-19) pandemic (December 2019 -- present) is a global public health crisis with no modern-day equivalent. Several lines of evidence suggest that it is reasonable to forecast a significant increase in cardiovascular (CV) related events and deaths immediately following, and for some time after, the current pandemic.[@bib0001], [@bib0002], [@bib0003] We examined cardiac catheterization laboratory activations at Harford Hospital in Hartford, Connecticut, United States (US) for ST-segment elevation myocardial infarctions (STEMI) and non-ST elevation acute coronary syndromes (NSTE-ACS) by month for December-April 2020, compared to the monthly average for the previous 4 years (2015--2019). These months were selected to quantify monthly changes in acute cardiac events since first knowledge of COVID-19 (late December 2019). The first case of suspected local transmission in the United States was reported on February 26, 2020 and the first case in Connecticut was confirmed on March 8, 2020. Local schools were closed March 17, 2020, and executive stay at home orders were put into effect on March 17, 2020.

Compared to historical averages ("expected"), there was a 38% increase in STEMI activations in February 2020, followed by 16% and 21% reductions in March and April, respectively ([Figure 1](#fig0001){ref-type="fig"} ). Compared with expected, there were 21%, 37%, and 80% reductions in NSTE-ACS activations for February, March, and April, respectively ([Figure 2](#fig0002){ref-type="fig"} ). Only 3 of 140 patients died February-April 2020; one delayed seeking medical attention for ∼24 hours for fear of COVID-19 infection and died from cardiogenic shock. Patients with documented time to presentation (n = 24) admitting March-April reported an average duration of 75 ± 196 hours from symptom onset to seeking medical attention. Patients had an average (±SD) age of 63 ± 14 years; 85% were white and 64% were men. Most were overweight (body mass index; mean ± SD: 30 ± 5, range: 21 to 42 kg/m^2^), current/former smokers (73%), and had chronic conditions (hypercholesterolemia, 63%; hypertension, 56%; diabetes mellitus, 22%). Most (85%) had no previous history of myocardial infarction.Figure 1STEMI activations per month before and after COVID-19 compared to historical averages.Figure 1Figure 2NSTE-ACS activations per month before and after COVID-19 compared to historical averages.Figure 2

These data, to our knowledge, are the first to confirm similar findings in the United States[@bib0004] reporting a 38% (95% confidence interval 26 to 49) reduction in STEMI activations from March 1 to March 31, 2020 compared with the preceding 14 months. These findings are consistent with data from Spain (40% reduction in STEMI in March)[@bib0005]; Austria (39% reduction in STEMI/NSTE-ACS in March)[@bib0006]; and poll results from US cardiologists (50% in STEMI/NSTE-ACS in February-March).[@bib0007] Our addition of data after March and including April highlights the magnitude and direction of the reduction in acute cardiac event presentation and can likely be extrapolated to a national level.

We observed a 38% *increase* in STEMI activations for February, which has not been described. Recent reports documenting reductions in post-COVID STEMI activations have evaluated January-February or February-March and have not evaluated February activations separately, and thus reductions in March activations may be greatly underestimated. This increase immediately prior to the epidemic needs verification, but may indicate an increase in events due to psychological stress since a 22% to 35% increase in STEMI/NSTE-ACS usually occurs immediately following the onset of a community crisis.[@bib0001], [@bib0002], [@bib0003] It is unclear why there was not a similar increase in NSTE-ACS with COVID-19. Future longitudinal studies will further elucidate the shape and magnitude of these early trends.

There are many possible explanations for the paradoxical *reduction* in acute CV events with COVID-19. Acute CV complications associated with COVID-19 could have increased morbidity and mortality in the most susceptible populations, a so-called harvesting effect. Out-of-hospital arrests could have increased, which will continue to be vastly underreported due to autopsy delay. Other hypotheses include reductions in behavioral triggers such as smoking and strenuous physical activity; reductions in environmental triggers; or increased volume of stable patients being temporarily medically managed at home. The most likely scenario is the possibility that symptomatic patients are not seeking care, as suggested by our observation that patients waited an average of 3 days after symptoms before presentation. Patient delay may be due to fear of infection, fear of overburdening the healthcare system, and/or loss of financial stability. Such delays are known to increase STEMI/NSTE-ACS complications and deaths. As the US reopens, there may be a surge in the number and severity of cardiac conditions worsened by delay in presentation. National media campaigns[@bib0008] should be expanded to educate and reinforce the importance of recognizing and seeking immediate medical attention for cardiac-related prodromal symptoms so as not to delay timely, lifesaving intervention.
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